ReviewOncotarget2016
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 104 citations in OpenAlex.
- Imaging of mass-forming intrahepatic cholangiocarcinoma: from detection to personalized treatments.Abdominal radiology (New York) · 2026Review
- Cholangiocarcinoma in the Era of Precision Medicine: Emerging Insights and Therapeutic Strategies.Current pharmaceutical design · 2026Review
- PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.Journal of hepatology · 2024Article
- Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.Cancers · 2024Review
- Emerging Therapies in Management of Cholangiocarcinoma.Cancers · 2024Review
- Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria.Journal of cancer research and clinical oncology · 2023Review
- Identification of immune related gene signature for predicting prognosis of cholangiocarcinoma patients.Frontiers in immunology · 2023Article
- Review
- Cancerization of ducts in hilar cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2022Article
- Article
- Novel Nitric Oxide Donor Dinitroazetidine-Coumarin Hybrids as Potent Anti-Intrahepatic Cholangiocarcinoma Agents.Molecules (Basel, Switzerland) · 2022Article
- Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.Scientific reports · 2022Article
- Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.Journal of immunotherapy and precision oncology · 2022Article
- The new insight of treatment in Cholangiocarcinoma.Journal of Cancer · 2022Review
- The role of tumor microenvironment reprogramming in primary liver cancer chemotherapy resistance.Frontiers in oncology · 2022Review
- Screening potential biomarkers of cholangiocarcinoma based on gene chip meta-analysis and small-sample experimental research.Frontiers in oncology · 2022Article
- Genetic Screens Identify a Context-Specific PI3K/p27Kip1 Node Driving Extrahepatic Biliary Cancer.Cancer discovery · 2021Article
- RNF43 overexpression attenuates the Wnt/β-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma.Oncology letters · 2021Article
- Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1.Aging · 2021Article
- Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.Journal of hepatology · 2021Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a relatively rare malignancy that arises from the epithelial cells of the intrahepatic, perihilar and distal biliary tree. Intrahepatic CCA (ICC) represents the second most common primary liver cancer, after hepatocellular cancer. Two-thirds of the patients with ICC present with locally advanced or metastatic disease. Despite standard treatment with gemcitabine and cisplatin, prognosis remains dismal with a median survival of less than one year. Several biological plausibilities can account for its poor clinical outcomes. First, despite the advent of next generation and whole exome sequencing, no oncogenic addiction loops have been validated as clinically actionable targets. Second, the anatomical, pathological and molecular heterogeneity, and rarity of CCA confer an ongoing challenge of instituting adequately powered clinical trials. Last, most of the studies were not biomarker-driven, which may undermine the potential benefit of targeted therapy in distinct subpopulations carrying the unique molecular signature. Recent whole genome sequencing efforts have identified known mutations in genes such as epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homolog (BRAF) and tumor protein p53 (TP53), novel mutations in isocitrate dehydrogenase (IDH), BRCA1-Associated Protein 1 (BAP1) and AT-rich interactive domain-containing protein 1A (ARID1A), and novel fusions such as fibroblast growth factor receptor 2 (FGFR2) and ROS proto-oncogene 1 (ROS1). In this review, we will discuss the evolving genetic landscape of CCA, with an in depth focus on novel fusions (e.g. FGFR2 and ROS1) and somatic mutations (e.g. IDH1/2), which are promising actionable molecular targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.